Aktuellt
SENASTE
Redeye has a positive take on today’s news that Alzecure has advanced ACD137 as a drug candidate as part of its TrkA-NAM project and will now move into preclinical development. While early stage, the target is well established in our view and could generate early interest from potential partners. Recently, the Japanese company Asahi Kasei also advanced its TrkA-NAM project into phase IIb targeting osteoarthritic pain, indicating current activity relating to the target. We will return with a more thorough view in relation to our Q4 update.
LÄS MER
